Beclometasone breath-activated inhalation - IVAX

Drug Profile

Beclometasone breath-activated inhalation - IVAX

Alternative Names: Beclazone 250 Easi-Breathe; Beclazone Easi-Breathe; Beclometasone breath-activated inhalation - Baker Norton; Beclometasone CFC-free Easi-Breathe; Beclomethasone breath-activated inhalation - Baker Norton; Beclomethasone breath-activated inhalation - IVAX; Beclomethasone CFC-free Easi-Breathe

Latest Information Update: 28 Jan 2014

Price : $50

At a glance

  • Originator IVAX Laboratories
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 01 Mar 2010 Withdrawn for Asthma in United Kingdom (Inhalation)
  • 01 Jul 2009 Withdrawn for Asthma in Mexico (Inhalation)
  • 01 Jan 2008 Withdrawn for Asthma in Czech Republic (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top